The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor
Abstract
Screening of random oligonucleotide libraries with SELEX [systematic evolution of ligands by exponential enrichment; Tuerk, C., & Gold, L. (1990) Science 249, 505-510] has emerged as a powerful method for identifying high-affinity nucleic acid ligands for a wide range of molecular targets. Nuclease sensitivity of unmodified RNA and DNA, however, imposes considerable restrictions on their use as therapeutics or diagnostics. Modified RNA in which pyrimidine 2'-hydroxy groups have been substituted with 2'-amino groups (2'-aminopyrimidine RNA) is known to be substantially more resistant to serum nucleases. We report here on the use of SELEX to identify high-affinity 2'-aminopyrimidine RNA ligands to a potent angiogenic factor, basic fibroblast growth factor (bFGF). High-affinity ligands with the same consensus primary structure have been isolated from two independent libraries of approximately 6 x 10(14) molecules containing 30 or 50 randomized positions. Compared to unmodified RNA with the same sequence, 2'-aminopyrimidine ligands are at least 1000-fold more stable in 90% human serum. The sequence information required for high-affinity binding to bFGF is contained within 24-26 nucleotides. The minimal ligand m21A (5'-GGUGUGUGGAAGACAGCGGGUGGUUC-3'; G = guanosine, A = adenosine, C = 2'-amino-2'-deoxycytidine, U = 2'-amino-2'-deoxyuridine, and C = 2'-amino-2'-deoxycytidine or deoxycytidine) binds to bFGF with an apparent dissociation constant (Kd) of 3.5 +/- 0.3) x 10(-10) M at 37 degrees C in phosphate-buffered saline (pH 7.4). Disassociation of m21A from bFGF is adequately described with a first-order rate constant of (1.96 +/- 0.08) x 10(-3) s-1 (t1/2 = 5.9 min). The calculated value for the association rate constant (kon = k(off)/Kd) was 5.6 x 10(6) M-1 s-1. Highly specific binding of m21A to bFGF was observed: binding to denatured bFGF, five proteins from the FGF family (acidic FGF, FGF-4, FGF-5, FGF-6, and FGF-7), and four other heparin binding proteins is substantially weaker under the same conditions with KdbFGF/Kdprotein values ranging from (4.1 +/- 1.4) x 10(-2) to > 10(-6). Heparin but not chondroitin sulfate competed for binding of m21A to bFGF. In cell culture, m21A inhibited [125I]bFGF binding to both low-affinity sites (ED50 approximately 1 nM) and high-affinity sites (ED50 approximately 3 nM) on CHO cells expressing transfected FGF receptor-1.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440
Moscatelli, D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35681-3 · Cited by 113
Cited by
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Jayasena, S. D. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1628 · Cited by 2,144
In Vitro Selection of Functional Nucleic Acids
Wilson, D. S., & Szostak, J. W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.611 · Cited by 1,206
Yao, J., Yang, M., & Duan, Y. (2014) · Chemical Reviews · doi:10.1021/cr200359p · Cited by 944
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Development of DNA aptamers using Cell-SELEX
Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M. B., & Tan, W. (2010) · Nature Protocols · doi:10.1038/nprot.2010.66 · Cited by 918
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Rohloff, J. C., Gelinas, A. D., Jarvis, T. C., Ochsner, U. A., Schneider, D. J., Gold, L., & Janjic, N. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.49 · Cited by 533
Nucleic Acid Selection and the Challenge of Combinatorial Chemistry
Osborne, S. E., & Ellington, A. D. (1997) · Chemical Reviews · doi:10.1021/cr960009c · Cited by 520
Aptamers as therapeutic and diagnostic agents
Brody, E. N., & Gold, L. (2000) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(99)00004-5 · Cited by 494
Discovery and development of anticancer aptamers
Ireson, C. R., & Kelland, L. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0172 · Cited by 481
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
Mirror-image RNA that binds D-adenosine
Klußmann, S., Nolte, A., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996) · Nature Biotechnology · doi:10.1038/nbt0996-1112 · Cited by 399
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Ni, X., Castanares, M., Mukherjee, A., & Lupold, S. E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797189600 · Cited by 349
An enzyme-linked oligonucleotide assay
Drolet, D. W., Moon-McDermott, L., & Romig, T. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0896-1021 · Cited by 335
Emerging clinical applications of RNA
Sullenger, B. A., & Gilboa, E. (2002) · Nature · doi:10.1038/418252a · Cited by 318
MODIFIED OLIGONUCLEOTIDES: Synthesis and Strategy for Users
Verma, S., & Eckstein, F. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.99 · Cited by 315
Shamah, S. M., Healy, J. M., & Cload, S. T. (2008) · Accounts of Chemical Research · doi:10.1021/ar700142z · Cited by 304
Recent progress in non-native nucleic acid modifications
McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Developing aptamers into therapeutics
White, R. R., Sullenger, B. A., & Rusconi, C. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11325 · Cited by 295
Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates
Lee, J. H., Yigit, M. V., Mazumdar, D., & Lu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.003 · Cited by 293
Aptamers as therapeutic and diagnostic reagents: problems and prospects
Osborne, S. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80102-0 · Cited by 288
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Schmidt, K. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh862 · Cited by 287
Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., & Janjić, N. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90032-2 · Cited by 284
Self-citationSELEX with modified nucleotides
Keefe, A. D., & Cload, S. T. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.06.028 · Cited by 283
Aptamer-based biosensor arrays for detection and quantification of biological macromolecules
McCauley, T. G., Hamaguchi, N., & Stanton, M. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00297-5 · Cited by 266
Rockey, W. M., Hernandez, F. J., Huang, S.-Y., Cao, S., Howell, C. A., Thomas, G. S., Liu, X. Y., Lapteva, N., Spencer, D. M., Mcnamara, J. O., et al. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0313 · Cited by 139
Metadata
- Authors
- Jellinek, D., Green, L. S., Bell, C., Lynott, C. K., Gill, N., Vargeese, C., Kirschenheuter, G., McGee, D. P. C., & Abesinghe, P.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-09-12
- Volume
- 34
- Issue
- 36
- Pages
- 11363-11372
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2087146563
- Cited by
- 215
- References
- 2
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.